Trial reportClinical obesity2025
Impact of weight on daily activities questionnaire in patients with overweight or obesity: Psychometric evaluation using data from the OASIS 1 trial.
Trial report in Clinical obesity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05035095. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Oral Semaglutide 50 mg Once Daily in Subjects With Overweight or Obesity (OASIS 1)
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The Impact of Weight on Daily Activities Questionnaire (IWDAQ) is a patient-reported outcome measure that uses a novel, adaptive design to assess the limitations in daily activities that are most important to individuals attempting to lose weight. During the first round of completing the IWDAQ, respondents are presented with 18 everyday activities that can be limited by excess weight and asked to choose the three activities they would most like to see improve with weight loss. They are then asked to rate the degree of limitation they experience with these three activities at baseline and at follow-up assessments. Using data from a weight-management clinical trial (OASIS 1, NCT05035095), we evaluated the IWDAQ's measurement properties, determined optimal scoring, and estimated thresholds of meaningful within-patient change. Our analyses demonstrated that the IWDAQ Composite Score offers a reliable and valid personalized measure of limitations in daily activities due to excess weight. The adaptive design of the IWDAQ ensures the patient-centricity of the measure, thereby complementing existing measures of functioning in the context of weight-management clinical trials. Evaluations using data from additional studies would be valuable in extending the psychometric evidence for the IWDAQ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.